Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/omeprazole/rifabutin - RedHill Biopharma

Drug Profile

Amoxicillin/omeprazole/rifabutin - RedHill Biopharma

Alternative Names: Amoxicillin/omeprazole/rifabutin; Amoxicillin/pantoprazole/rifabutin; Amoxicillin/rifabutin/omeprazole; Heliconda; Omeprazole/amoxicillin/rifabutin; RHB-105; Rifabutin/amoxicillin/omeprazole; TALICIA

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antituberculars; Antiulcers; Benzimidazoles; Gastric antisecretories; Penicillins; Rifamycins; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA-directed RNA polymerase inhibitors; Penicillin-binding protein inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Helicobacter infections

Most Recent Events

  • 04 Nov 2019 Registered for Helicobacter infections (Treatment-naive) in USA (PO)
  • 04 Nov 2019 RedHill Biopharma intends to launch TALICIA® in the USA in the first quarter of 2020
  • 03 Jul 2019 FDA assigns PDUFA action date of 02/11/2019 for Amoxicillin/omeprazole/rifabutin for Helicobacter infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top